fenofibrate has been researched along with obeticholic acid in 6 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 4 (66.67) | 24.3611 |
2020's | 2 (33.33) | 2.80 |
Authors | Studies |
---|---|
Fenaux, M; Halcomb, RL; Jones, CT; Romero, FA; Xu, Y | 1 |
Czul, F; Levy, C | 1 |
Strassburg, CP | 1 |
Bahar, R; Bowlus, CL; Liu, CH; Wong, KA | 1 |
Hirschfield, GM; Webb, GJ | 1 |
Albillos, A; Álvarez-Navascués, C; Andrade, RJ; Arencibia, A; Berenguer, M; Casado, M; Chahri, N; De la Cruz, G; Diago, M; Estevez, P; Fábrega, E; Fernandez-Bonilla, E; Fernández-Rodriguez, CM; Ferre-Aracil, C; Gallego-Moya, A; Gómez-Camarero, J; Gómez-Domínguez, E; González-Santiago, JM; Hernández-Guerra, M; Hijona, L; Horta, D; Molina, E; Morillas, RM; Parés, A; Pérez-Medrano, IM; Reig, A; Romero-Gomez, M; Sala, M; Suárez, F; Vargas, V; Vergara, M | 1 |
5 review(s) available for fenofibrate and obeticholic acid
Article | Year |
---|---|
The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease.
Topics: Animals; Anticholesteremic Agents; Drug Delivery Systems; Drug Development; Humans; Hypoglycemic Agents; Lipid Metabolism; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease; Obesity; PPAR gamma; Protein Structure, Tertiary | 2020 |
Novel Therapies on Primary Biliary Cirrhosis.
Topics: Abatacept; Anti-Retroviral Agents; Antibodies, Monoclonal, Humanized; Bezafibrate; Chenodeoxycholic Acid; Cholagogues and Choleretics; Fenofibrate; Glucocorticoids; Humans; Hypolipidemic Agents; Immunologic Factors; Liver Cirrhosis, Biliary; Mesenchymal Stem Cell Transplantation; Receptors, Cytoplasmic and Nuclear; Rituximab; Ursodeoxycholic Acid; Ustekinumab | 2016 |
[Modern treatment of primary biliary cholangitis].
Topics: Bezafibrate; Budesonide; Chenodeoxycholic Acid; Cohort Studies; Female; Fenofibrate; Humans; Liver Cirrhosis, Biliary; Liver Transplantation; Male; Multicenter Studies as Topic; PPAR alpha; Pregnancy; Prognosis; Quality of Life; Receptors, Cytoplasmic and Nuclear; Risk Assessment; Treatment Outcome; Ursodeoxycholic Acid | 2018 |
Current Treatment Options for Primary Biliary Cholangitis.
Topics: Alkaline Phosphatase; Bezafibrate; Chenodeoxycholic Acid; Cholagogues and Choleretics; Comorbidity; Drug Therapy, Combination; Fenofibrate; Fibroblast Growth Factors; Humans; Hypolipidemic Agents; Immunosuppressive Agents; Liver Cirrhosis, Biliary; Malnutrition; Osteoporosis; Peroxisome Proliferator-Activated Receptors; Receptors, Cytoplasmic and Nuclear; Ursodeoxycholic Acid | 2018 |
Work in Progress: Drugs in Development.
Topics: Abatacept; Acetates; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Bezafibrate; CD40 Antigens; CD40 Ligand; Chalcones; Chemokine CX3CL1; Chenodeoxycholic Acid; Cholic Acids; Drug Development; Fenofibrate; Fibroblast Growth Factors; Humans; Hypolipidemic Agents; Immunosuppressive Agents; Janus Kinase Inhibitors; Liver Cirrhosis, Biliary; Methylamines; Peroxisome Proliferator-Activated Receptors; PPAR alpha; PPAR delta; PPAR gamma; Propionates; Pruritus; Receptors, Cytoplasmic and Nuclear; Receptors, G-Protein-Coupled; Thiazepines; Triazoles; Ustekinumab | 2018 |
1 other study(ies) available for fenofibrate and obeticholic acid
Article | Year |
---|---|
Obeticholic Acid and Fibrates in Primary Biliary Cholangitis: Comparative Effects in a Multicentric Observational Study.
Topics: Bezafibrate; Chenodeoxycholic Acid; Female; Fenofibrate; Humans; Liver Cirrhosis, Biliary; Male; Middle Aged; Retrospective Studies; Treatment Outcome | 2021 |